Fundraising Fox

Comanche Biopharma

Concord, US · Founded 2020 · Delaware corporation · 33 employees on LinkedIn · 6 known investors

Find your way into Comanche Biopharma

346 people in our graph share verified history with the Comanche Biopharma team — schools, employers, funds. One of them is your warm intro.

Annie Kadavyunlockedknows Mike Young · together at Stanford University Graduate School of Business (overlapped)
×5knows the team · via Stanford University Graduate School of Business
×6knows the team · via Massachusetts General Hospital

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.

BiotechFemTechHealthtech

Founders & leadership

Comanche Biopharma was founded in 2020 by Mike Young and T Scott Johnson.

MYMike Young
Mike YounginCo-Founder & PresidentMike Young is founder of Comanche Biopharma, a biopharmaceutical company developing an investigational siRNA medicine targeting a root cause of preterm preeclampsia in pregnant women.
TST Scott Johnson
T Scott JohnsoninCo-Founder and CEO
PAPaul Antinori
Paul AntinoriExecutive
AAAllison August
Allison AugustinChief Medical Officer2022–2025
TS
Thomas Scott JohnsonNamed on SEC filing

Board

BBBrendan Bulik-Sullivan
Brendan Bulik-SullivaninBoard directorInvestor at GV (Google Ventures)
MM
Muzammil MansuriBoard director
KPKetan Patel
Ketan PatelinBoard directorManaging Partner at F-Prime Capital Partners
AL
Arthur LevinBoard director
AT
Ann TaylorBoard director
CM
Clive MeanwellBoard director
AF
Allyson FelixBoard director

Investors · 6

Atlas Venture✓ verifiedCambridge · $500K – $1M
GV (Google Ventures)✓ verifiedMountain View · $250K – $50M
Broadview VenturesBoston
F-Prime CapitalCambridge · $3M – $10M
Lilly Asia VenturesreportedHong Kong
New Enterprise Associates (NEA)reported · 2 sourcesMenlo Park · $200K – $40M

Funding

SEC filings, press & company announcements

$73.6M disclosed across 2 of 3 rounds · 2021–2025

▶$37.5MraisedJan 2024 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ann TaylorDirector
  • Brendan Bulik-SullivanDirector
  • Muzammil MansuriDirector
  • Allison AugustExecutive Officer
  • Paul AntinoriExecutive Officer
  • Allyson FelixDirector
  • David GrayzelDirector
  • Thomas Scott JohnsonExecutive Officer, Director
  • Scott GottliebDirector
  • Ketan PatelDirector
  • Michael YoungExecutive Officer
Offering amount
$75M
Amount sold
$37.5M
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$36.1MraisedMay 2023 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Arthur LevinDirector
  • Brendan Bulik-SullivanDirector
  • Muzammil MansuriDirector
  • Paul AntinoriExecutive Officer
  • Allison AugustExecutive Officer
  • Ann TaylorDirector
  • Clive MeanwellDirector
  • Allyson FelixDirector
  • Ketan PatelDirector
  • Michael YoungExecutive Officer
  • Thomas Scott JohnsonExecutive Officer, Director
Offering amount
$36.1M
Amount sold
$36.1M
First sale
Jun 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Xoma NASDAQ: XOMA www.xoma.com4 shared keywordsXOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
Medscape3 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Comanche Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Comanche Biopharma Secures $90M Series B to Advance Groundbreaking siRNA Therapy for Preterm Preeclampsia | SignalBasetrysignalbase.com · Feb 2025Comanche Biopharma Raise $75 Million Series B Financing - European Pharmaceutical Manufacturerpharmaceuticalmanufacturer.media · Jan 2024Comanche raises $75m to develop preeclampsia therapyclinicaltrialsarena.com · Jan 2024Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to ... | Region | eagletribune.comeagletribune.com · Jan 2024Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsiaglobenewswire.com · Jan 2024Comanche Biopharma raises $75M to fund preeclampsia drug testing | BioPharma Divebiopharmadive.com · Jan 2024

Frequently asked questions

What does Comanche Biopharma do?
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.
Who founded Comanche Biopharma?
Comanche Biopharma was founded by Mike Young, T Scott Johnson in 2020.
Who are Comanche Biopharma's investors?
Comanche Biopharma's investors include Atlas Venture, GV (Google Ventures), Broadview Ventures, F-Prime Capital, Lilly Asia Ventures, New Enterprise Associates (NEA).
How much funding has Comanche Biopharma raised?
Comanche Biopharma has disclosed $73.6M raised across 2 of its 3 known rounds.
Where is Comanche Biopharma headquartered?
Comanche Biopharma is headquartered in Concord, US.